2013
Genomic Analysis of Non-NF2 Meningiomas Reveals Mutations in TRAF7, KLF4, AKT1, and SMO
Clark VE, Erson-Omay EZ, Serin A, Yin J, Cotney J, Özduman K, Avşar T, Li J, Murray PB, Henegariu O, Yilmaz S, Günel JM, Carrión-Grant G, Yılmaz B, Grady C, Tanrıkulu B, Bakırcıoğlu M, Kaymakçalan H, Caglayan AO, Sencar L, Ceyhun E, Atik AF, Bayri Y, Bai H, Kolb LE, Hebert RM, Omay SB, Mishra-Gorur K, Choi M, Overton JD, Holland EC, Mane S, State MW, Bilgüvar K, Baehring JM, Gutin PH, Piepmeier JM, Vortmeyer A, Brennan CW, Pamir MN, Kılıç T, Lifton RP, Noonan JP, Yasuno K, Günel M. Genomic Analysis of Non-NF2 Meningiomas Reveals Mutations in TRAF7, KLF4, AKT1, and SMO. Science 2013, 339: 1077-1080. PMID: 23348505, PMCID: PMC4808587, DOI: 10.1126/science.1233009.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBrain NeoplasmsChromosomes, Human, Pair 22DNA Mutational AnalysisFemaleGenes, Neurofibromatosis 2Genomic InstabilityGenomicsHumansKruppel-Like Factor 4Kruppel-Like Transcription FactorsMaleMeningeal NeoplasmsMeningiomaMiddle AgedMutationNeoplasm GradingProto-Oncogene Proteins c-aktReceptors, G-Protein-CoupledSmoothened ReceptorTumor Necrosis Factor Receptor-Associated Peptides and Proteins
2010
Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma†
Kunwar S, Chang S, Westphal M, Vogelbaum M, Sampson J, Barnett G, Shaffrey M, Ram Z, Piepmeier J, Prados M, Croteau D, Pedain C, Leland P, Husain SR, Joshi BH, Puri RK, Group F. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma†. Neuro-Oncology 2010, 12: 871-881. PMID: 20511192, PMCID: PMC2940677, DOI: 10.1093/neuonc/nop054.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntineoplastic AgentsBrain NeoplasmsCarmustineCatheters, IndwellingConvectionDecanoic AcidsDrug Administration RoutesExotoxinsFemaleGlioblastomaHumansInterleukin-13Kaplan-Meier EstimateMagnetic Resonance ImagingMaleMiddle AgedNeoplasm Recurrence, LocalPolyestersRecombinant Fusion ProteinsYoung AdultConceptsConvection-enhanced deliveryCintredekin besudotoxGliadel wafersMedian survivalTumor resectionGlioblastoma multiformeEfficacy-evaluable populationAdverse event profileHealth-related qualityPhase III evaluationTime of randomizationEvaluable populationTertiary endpointsPrimary endpointAdult patientsBaseline characteristicsFirst recurrenceOverall survivalPulmonary embolismActive comparatorTreatment armsIL13-PE38QQRIntraparenchymal catheterSurvival differencesGBM patients
2009
Primary, non-exophytic, optic nerve germ cell tumors
DiLuna ML, Two AM, Levy GH, Patel T, Huttner AJ, Duncan CC, Piepmeier JM. Primary, non-exophytic, optic nerve germ cell tumors. Journal Of Neuro-Oncology 2009, 95: 437-443. PMID: 19554263, DOI: 10.1007/s11060-009-9941-1.Peer-Reviewed Original ResearchConceptsGerm cell tumorsOptic chiasmatic gliomasMalignant mixed germ cell tumorMixed germ cell tumorOptic chiasmCell tumorsOptic chiasm tumorAdrenal axis dysfunctionSub-frontal approachChiasm gliomaChiasmatic gliomasAxis dysfunctionBiopsy confirmationProgressive symptomsVisual lossCase seriesFirst patientTreatment regimensPterional craniotomyDiabetes insipidusTissue diagnosisTissue biopsiesTumorsPatientsChiasm
2007
Direct Intracerebral Delivery of Cintredekin Besudotox (IL13-PE38QQR) in Recurrent Malignant Glioma: A Report by the Cintredekin Besudotox Intraparenchymal Study Group
Kunwar S, Prados MD, Chang SM, Berger MS, Lang FF, Piepmeier JM, Sampson JH, Ram Z, Gutin PH, Gibbons RD, Aldape KD, Croteau DJ, Sherman JW, Puri RK. Direct Intracerebral Delivery of Cintredekin Besudotox (IL13-PE38QQR) in Recurrent Malignant Glioma: A Report by the Cintredekin Besudotox Intraparenchymal Study Group. Journal Of Clinical Oncology 2007, 25: 837-844. PMID: 17327604, DOI: 10.1200/jco.2006.08.1117.Peer-Reviewed Original ResearchConceptsConvection-enhanced deliveryIntracerebral convection-enhanced deliveryCintredekin besudotoxRecurrent malignant gliomaMalignant gliomasGlioblastoma multiformeMedian survivalCatheter placementTumor resectionInfusion durationProcedure-related adverse eventsFavorable risk-benefit profilePhase I clinical studyBetter drug distributionDirect intracerebral deliveryOptimal drug distributionOverall median survivalPortion of patientsRisk-benefit profileDevastating brain tumorDrug distributionAdverse eventsHigh tissue concentrationsIntracerebral deliveryTumor necrosis
2006
The Interactions of Polarographic Measurements of Oxygen Tension and Histological Grade in Human Glioma
Lally BE, Rockwell S, Fischer DB, Collingridge DR, Piepmeier JM, Knisely JP. The Interactions of Polarographic Measurements of Oxygen Tension and Histological Grade in Human Glioma. The Cancer Journal 2006, 12: 461-466. PMID: 17207315, DOI: 10.1097/00130404-200611000-00005.Peer-Reviewed Original ResearchConceptsHistological gradeHigh-grade gliomasLow-grade gliomasTumor oxygen tensionUnivariate analysisOxygen tensionGrade gliomasSignificant independent prognostic indicatorExtent of surgeryType of anesthesiaIndependent prognostic indicatorEppendorf pO2 histographTissue oxygen tensionNormal brain tissueImplications of hypoxiaOverall survivalProspective trialPatient ageEntire cohortPrognostic indicatorPatient genderPoor survivalMedian pO2PatientsPO2 histographDiffusion MRI in the early diagnosis of malignant glioma
Baehring JM, Bi WL, Bannykh S, Piepmeier JM, Fulbright RK. Diffusion MRI in the early diagnosis of malignant glioma. Journal Of Neuro-Oncology 2006, 82: 221-225. PMID: 17029014, DOI: 10.1007/s11060-006-9273-3.Peer-Reviewed Original ResearchConceptsDiffusion-weighted imagingMalignant gliomasApparent diffusion coefficient (ADC) mapsCentral necrosisNodular enhancing lesionsResultsOf 89 patientsTimely definitive diagnosisSubset of patientsClinical decision-making processBrain Tumor CenterFurther tumor growthHigh-grade gliomasTypical radiographic presentationTime of imagingSubset of casesLow signal intensityDiffusion coefficient mapsConclusionsThe diagnosisDefinitive diagnosisEloquent areasEnhancing lesionsMass lesionRadiographic presentationRim enhancementInclusion criteriaChondrosarcoma of the Skull Base
Baehring JM, Piepmeier J, Duncan C, Liebsch N, Ogle E, Kim J. Chondrosarcoma of the Skull Base. Journal Of Neuro-Oncology 2006, 76: 49-49. PMID: 16402277, DOI: 10.1007/s11060-005-5981-3.Peer-Reviewed Original Research
2005
Novel Tumor-Specific Isoforms of BEHAB/Brevican Identified in Human Malignant Gliomas
Viapiano MS, Bi WL, Piepmeier J, Hockfield S, Matthews RT. Novel Tumor-Specific Isoforms of BEHAB/Brevican Identified in Human Malignant Gliomas. Cancer Research 2005, 65: 6726-6733. PMID: 16061654, DOI: 10.1158/0008-5472.can-05-0585.Peer-Reviewed Original ResearchConceptsBEHAB/brevicanHigh-grade gliomasMalignant gliomasBrain tumorsNew potential therapeutic targetsPrimary brain tumorsNormal adult brainDeadly brain tumorCentral nervous systemPotential therapeutic targetLow-grade gliomasHuman malignant gliomasNew therapeutic strategiesPathologic courseSimilar histologyBenign gliomasAdult brainTherapeutic strategiesDiffuse invasionTherapeutic targetGlioma progressionNervous systemInvasive abilityBrain tissueGliomas
2004
Tumors of the posterior third ventricle and pineal region: ependymoma and germinoma
Baehring J, Vives K, Duncan C, Piepmeier J, Bannykyh S. Tumors of the posterior third ventricle and pineal region: ependymoma and germinoma. Journal Of Neuro-Oncology 2004, 70: 273-274. PMID: 15674486, DOI: 10.1007/s11060-004-5395-7.Peer-Reviewed Original ResearchMelanocytoma
Bannykh S, Piepmeier J, Baehring J. Melanocytoma. Journal Of Neuro-Oncology 2004, 70: 35-35. PMID: 15527105, DOI: 10.1023/b:neon.0000040895.76760.69.Peer-Reviewed Original ResearchNon-enhancing de novo glioblastoma: report of two cases
Cohen-Gadol AA, DiLuna ML, Bannykh SI, Piepmeier JM, Spencer DD. Non-enhancing de novo glioblastoma: report of two cases. Neurosurgical Review 2004, 27: 281-285. PMID: 15449198, DOI: 10.1007/s10143-004-0346-5.Peer-Reviewed Original ResearchConceptsRing-enhancing lesionsLow-grade lesionsSecond patientMalignant gliomasRight medial temporal lobe lesionInitial MRI evaluationTraditional imaging findingsDe novo lesionsNew-onset seizuresMedial temporal lobe lesionsT2 signal changeRight precentral gyrusTemporal lobe lesionsMedial temporal lesionsRight frontal lesionDe novo glioblastomaEarly MRINovo lesionsNeurological examinationSubsequent resectionImaging findingsFirst patientMRI evaluationTumor suggestiveTemporal lesions
1999
Polarographic measurements of oxygen tension in human glioma and surrounding peritumoural brain tissue
Collingridge D, Piepmeier J, Rockwell S, Knisely J. Polarographic measurements of oxygen tension in human glioma and surrounding peritumoural brain tissue. Radiotherapy And Oncology 1999, 53: 127-131. PMID: 10665789, DOI: 10.1016/s0167-8140(99)00121-8.Peer-Reviewed Original Research
1997
Low-grade gliomas of chronic epilepsy: A distinct clinical and pathological entity
Bartolomei J, Christopher S, Vives K, Spencer D, Piepmeier J. Low-grade gliomas of chronic epilepsy: A distinct clinical and pathological entity. Journal Of Neuro-Oncology 1997, 34: 79-84. PMID: 9210054, DOI: 10.1023/a:1005711321343.Peer-Reviewed Original ResearchConceptsLow-grade gliomasChronic epilepsyDysembryoplastic neuroepithelial tumorPathological entityLong-term patient outcomesSpecific pathological entityManagement of patientsResults of patientsDistinct pathological entityLack of mortalityPreoperative seizuresNeuroepithelial tumorsTumor recurrencePatient outcomesAnaplastic transformationEpilepsySame tumorGliomasCortical locationTumorsPatientsRecurrenceSeizuresPopulationMortalityAdministration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study.
Bracken MB, Shepard MJ, Holford TR, Leo-Summers L, Aldrich EF, Fazl M, Fehlings M, Herr DL, Hitchon PW, Marshall LF, Nockels RP, Pascale V, Perot PL, Piepmeier J, Sonntag VK, Wagner F, Wilberger JE, Winn HR, Young W. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. JAMA 1997, 277: 1597-604. PMID: 9168289, DOI: 10.1001/jama.277.20.1597.Peer-Reviewed Original ResearchConceptsAcute spinal cord injurySpinal cord injuryNational Acute Spinal Cord Injury StudyFunctional Independence MeasureHours of injuryCord injuryTirilazad groupRegimen groupMethylprednisolone infusionAcute Spinal Cord Injury StudySpinal Cord Injury StudySpinal cord injury centerEfficacy of methylprednisoloneImproved motor recoveryMotor recovery rateAdministration of methylprednisoloneMotor function changesSteroid therapyMethylprednisolone groupSevere sepsisTirilazad mesylateMotor recoveryControlled TrialsInitial presentationIntravenous bolus
1996
BEHAB (brain enriched hyaluronan binding) is expressed in surgical samples of glioma and in intracranial grafts of invasive glioma cell lines.
Jaworski D, Kelly G, Piepmeier J, Hockfield S. BEHAB (brain enriched hyaluronan binding) is expressed in surgical samples of glioma and in intracranial grafts of invasive glioma cell lines. Cancer Research 1996, 56: 2293-8. PMID: 8625302.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAnimalsBiomarkers, TumorBrain NeoplasmsBrevicanCarrier ProteinsChild, PreschoolChondroitin Sulfate ProteoglycansFemaleGliomaHumansHyaluronic AcidIn Situ HybridizationLectins, C-TypeMaleMiddle AgedNeoplasm InvasivenessNeoplasm ProteinsNeoplasm TransplantationNerve Tissue ProteinsRatsRats, Inbred LewRats, Sprague-DawleyTumor Cells, CulturedConceptsGlioma cell linesSurgical samplesIntracranial graftsCell linesAdult human cortexInvasive glioma cell linesBrain metastasesNonglial tumorsNoninvasive cell linesMalignant gliomasExtracellular brainNormal brainTumor invasionHyaluronan-binding proteinHuman cortexGliomasTumorsInvasive behaviorStandard cell culture conditionsGraftBrainBEHABCell culture conditionsSelective markerMetastasisVariations in the natural history and survival of patients with supratentorial low-grade astrocytomas.
Piepmeier J, Susan Christopher R, Spencer D, Byrne T, Kim J, Knisel J, Lacy J, Tsukerman L, Makuch R. Variations in the natural history and survival of patients with supratentorial low-grade astrocytomas. Neurosurgery 1996, 38: 872-8; discussion 878-9. PMID: 8727811, DOI: 10.1097/00006123-199605000-00002.Peer-Reviewed Original ResearchConceptsLow-grade astrocytomasGross total resectionChronic epilepsySupratentorial low-grade astrocytomasNatural historyGross total tumor resectionImmediate postoperative radiotherapyExtent of surgerySurvival of patientsTen-year survivalPopulation of patientsUse of radiotherapyRisk of recurrenceHigh-grade lesionsLength of survivalMore malignant tumorsTypes of symptomsAggressive surgeryPostoperative radiotherapyPreoperative symptomsConsecutive patientsBetter prognosisTumor recurrenceTumor resectionMalignant tumorsA phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain
Halperin E, Herndon J, Schold S, Brown M, Vick N, Cairncross J, Macdonald D, Gaspar L, Fischer B, Dropcho E, Rosenfeld S, Morowitz R, Piepmeier J, Hait W, Byrne T, Salter M, Imperato J, Khandekar J, Paleologos N, Burger P, Bentel G, Friedman A. A phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain. International Journal Of Radiation Oncology • Biology • Physics 1996, 34: 793-802. PMID: 8598355, DOI: 10.1016/0360-3016(95)02025-x.Peer-Reviewed Original ResearchConceptsExternal beam radiotherapyKarnofsky performance statusMedian survivalSurvival benefitERT groupAnaplastic gliomasBeam radiotherapyMitomycin CVs. 11.4 monthsProportion of patientsSignificant survival benefitPossible survival benefitTreatment of adultsYears of ageBCNU groupPerformance statusProspective trialHistologic diagnosisMalignant gliomasMito groupStereotactic biopsyPatientsGreater riskFourth weekThird day
1995
Verapamil treatment attenuates immunoreactive GFAP at cerebral cortical lesion site
Klepper S, Naftolin F, Piepmeier J. Verapamil treatment attenuates immunoreactive GFAP at cerebral cortical lesion site. Brain Research 1995, 695: 245-249. PMID: 8556338, DOI: 10.1016/0006-8993(95)00825-b.Peer-Reviewed Original ResearchConceptsGFAP-like immunoreactivityGlial fibrillary acidic proteinSaline groupCortical lesionsLocal injectionNeedle lesionsLesion siteL-type calcium channel blockerCerebral cortical lesionsCortical lesion sitesL-type calcium channelsCalcium channel blockersSprague-Dawley ratsImmunoreactive glial fibrillary acidic proteinTime of lesioningFibrillary acidic proteinH post lesionTransmembrane calcium fluxVerapamil treatmentReactive astrocytesPost lesionContralateral hemisphereChannel blockersCalcium channelsAntigen labeling
1993
Low-grade astrocytomas may arise from different astrocyte lineages.
Piepmeier J, Fried I, Makuch R. Low-grade astrocytomas may arise from different astrocyte lineages. Neurosurgery 1993, 33: 627-32. PMID: 8232801, DOI: 10.1227/00006123-199310000-00010.Peer-Reviewed Original ResearchConceptsLow-grade astrocytomasGlial fibrillary acidic protein-positive cellsFibrillary acidic proteinProtein-positive cellsAstrocyte lineagePreoperative symptomsAnti-glial fibrillary acidic proteinAcidic proteinGlial fibrillary acidic proteinLong preoperative historyCommon histological featuresDifferent clinical manifestationsPercentage of cellsPreoperative historyClinical manifestationsHistological featuresImaging featuresRate of proliferationImmunohistochemical analysisAstrocytic phenotypeNeoplastic cellsType 2White matterAstrocytomasTumors
1990
The effect of calmodulin inhibitors with bleomycin on the treatment of patients with high grade gliomas.
Hait W, Byrne T, Piepmeier J, Durivage H, Choudhury S, Davis C, Gates J. The effect of calmodulin inhibitors with bleomycin on the treatment of patients with high grade gliomas. Cancer Research 1990, 50: 6636-40. PMID: 1698540.Peer-Reviewed Original ResearchConceptsCentral nervous systemClinical trialsNormal brainNervous systemPhase II clinical trialPhase I clinical trialFatal pulmonary toxicityObjective tumor responseTreatment of patientsHigh-grade gliomasComplete responseCombination therapyPulmonary toxicityTumor responseFatal malignancyMalignant gliomasPreclinical modelsPharmacological characteristicsGrade gliomasGlioblastoma multiformePatientsGliomasRat cerebrumCalmodulin inhibitorsBleomycin